INmune Bio Inc logo

INMB - INmune Bio Inc Share Price

$11.22 0.3  3.0%

Last Trade - 13/04/21

Small Cap
Market Cap £87.7m
Enterprise Value £71.7m
Revenue £7.94k
Position in Universe 5013th / 6848
Unlock INMB Revenue
Relative Strength (%)
1m -32.2%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -62.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.011 1.45
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, INmuneBio Inc revenues increased from $0K to $11K. Net lossincreased 58% to $12.1M. Revenues reflect an increase indemand for the Company's products and services due tofavorable market conditions. Higher net loss reflectsResearch and development - Balancing val increase from$1.5M to $5.3M (expense), Stock-based Compensation in SGAincrease of 8% to $2.5M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for INMB
Graphical History


INMB Revenue Unlock INMB Revenue

Net Income

INMB Net Income Unlock INMB Revenue

Normalised EPS

INMB Normalised EPS Unlock INMB Revenue

PE Ratio Range

INMB PE Ratio Range Unlock INMB Revenue

Dividend Yield Range

INMB Dividend Yield Range Unlock INMB Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
INMB EPS Forecasts Unlock INMB Revenue
Profile Summary

Inmune Bio Inc. is a clinical-stage pharmaceutical immunotherapy company. The Company is focused on developing strategies for oncology that focus on re-engineering and harnessing the innate immune system to treat the patient’s cancer. The Company’s product candidates (INMB) target cells of the innate immune system that include natural killer cells (NK cells) and myeloid derived suppressor cells, (MDSC cells). The NK cell of the innate immune system has two primary functions, such as to kill virally infected cells and to kill cancer cells. Its INB03 is a protein biologic that has beneficial effects in patients with cancer. Its initial focus is on its ability to inhibit proliferation and function of myeloid-derived suppressor cells (MDSC).

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated September 25, 2015
Public Since February 4, 2019
No. of Shareholders: 35
No. of Employees: 5
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 10,746,948
Free Float (0.0%)
Eligible for
INMB Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for INMB
Upcoming Events for INMB
Thursday 30th September, 2021 Estimate
INmune Bio Inc Annual Shareholders Meeting
Frequently Asked Questions for INmune Bio Inc
What is the INmune Bio Inc share price?

As of 13/04/21, shares in INmune Bio Inc are trading at $11.22, giving the company a market capitalisation of £87.7m. This share price information is delayed by 15 minutes.

How has the INmune Bio Inc share price performed this year?

Shares in INmune Bio Inc are currently trading at $11.22 and the price has moved by 0.214k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the INmune Bio Inc price has moved by 0.117k% over the past year.

What are the analyst and broker recommendations for INmune Bio Inc?

Of the analysts with advisory recommendations for INmune Bio Inc, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for INmune Bio Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will INmune Bio Inc next release its financial results?

INmune Bio Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the INmune Bio Inc dividend yield?

INmune Bio Inc does not currently pay a dividend.

Does INmune Bio Inc pay a dividend?

INmune Bio Inc does not currently pay a dividend.

When does INmune Bio Inc next pay dividends?

INmune Bio Inc does not currently pay a dividend.

How do I buy INmune Bio Inc shares?

To buy shares in INmune Bio Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of INmune Bio Inc?

Shares in INmune Bio Inc are currently trading at $11.22, giving the company a market capitalisation of £87.7m.

Where are INmune Bio Inc shares listed? Where are INmune Bio Inc shares listed?

Here are the trading details for INmune Bio Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: INMB
What kind of share is INmune Bio Inc?

Based on an overall assessment of its quality, value and momentum, INmune Bio Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a INmune Bio Inc share price forecast 2021?

Shares in INmune Bio Inc are currently priced at $11.22. At that level they are trading at 0.164% discount to the analyst consensus target price of 0.00.

Analysts covering INmune Bio Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.05 for the next financial year.

How can I tell whether the INmune Bio Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like INmune Bio Inc. Over the past six months, the relative strength of its shares against the market has been 8.84%. At the current price of $11.22, shares in INmune Bio Inc are trading at -8.82% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the INmune Bio Inc PE Ratio?

We were not able to find PE ratio data for INmune Bio Inc.

Who are the key directors of INmune Bio Inc?

We were unable to find the directors for INmune Bio Inc.

Who are the major shareholders of INmune Bio Inc?

Here are the top five shareholders of INmune Bio Inc based on the size of their shareholding:

Xencor Inc Corporation
Percentage owned: 14.75% (1.59m shares)
Tesi (Raymond Joseph) Individual Investor
Percentage owned: 14.34% (1.54m shares)
Lowdell (Mark William) Individual Investor
Percentage owned: 14.02% (1.51m shares)
Moss (David J.) Individual Investor
Percentage owned: 11.38% (1.22m shares)
Toucan Capital Corp Venture Capital
Percentage owned: 6.51% (700k shares)
Similar to INMB
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.